Cancer
Cancer Ongoing 2021 North Shore NSW

KEYNOTE-057

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory or Intolerant to BCG Therapy.

Trial overview

Disease
Genitourinary cancer
Topic
KEYNOTE-057
Eligibility criteria
  • Non-muscle-invasive bladder cancer
  • Failed BCG therapy
Study details

The treatment is immunotherapy 3 weekly. While on treatment there will be regular blood tests, urine tests, cystoscopies, and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore NSW